290 related articles for article (PubMed ID: 33296985)
1. Systemic erythematous lupus after treatment of multiple sclerosis with alemtuzumab.
Adamec I; Mayer M; Ćorić M; Ruška B; Habek M
Mult Scler Relat Disord; 2020 Nov; 46():102589. PubMed ID: 33296985
[TBL] [Abstract][Full Text] [Related]
2. An unforeseen reality: Hemophagocytic lymphohistiocytosis following alemtuzumab treatment for a multiple sclerosis.
Ošep AB; Brecl E; Škerget M; Savšek L
Clin Neurol Neurosurg; 2023 May; 228():107675. PubMed ID: 36965418
[TBL] [Abstract][Full Text] [Related]
3. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
Cohen JA; Coles AJ; Arnold DL; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Fisher E; Brinar VV; Giovannoni G; Stojanovic M; Ertik BI; Lake SL; Margolin DH; Panzara MA; Compston DA;
Lancet; 2012 Nov; 380(9856):1819-28. PubMed ID: 23122652
[TBL] [Abstract][Full Text] [Related]
4. Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD).
Vukusic S; Brassat D; de Seze J; Izquierdo G; Lysandropoulos A; Moll W; Vanopdenbosch L; Arque MJ; Kertous M; Rufi P; Oreja-Guevara C
Mult Scler Relat Disord; 2019 Apr; 29():7-14. PubMed ID: 30654246
[TBL] [Abstract][Full Text] [Related]
5. Case Report: Delayed Alemtuzumab-Induced Concurrent Neutropenia and Thrombocytopenia in Relapsing-Remitting Multiple Sclerosis.
Ganju A; Stock JC; Jordan K
J Pharm Pract; 2023 Feb; 36(1):168-172. PubMed ID: 34169768
[TBL] [Abstract][Full Text] [Related]
6. A real-life study of alemtuzumab in persons with multiple sclerosis: Kuwait's experience.
Alroughani R; AlMojel M; Al-Hashel J; Ahmed SF
Mult Scler Relat Disord; 2023 Jun; 74():104712. PubMed ID: 37054581
[TBL] [Abstract][Full Text] [Related]
7. Auto-immune hepatitis in a patient with multiple sclerosis treated with alemtuzumab.
El Sankari S; Dahlqvist G; Monino L; van Pesch V
Acta Neurol Belg; 2018 Jun; 118(2):331-333. PubMed ID: 29713905
[No Abstract] [Full Text] [Related]
8. Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis.
Hartung HP; Aktas O; Boyko AN
Mult Scler; 2015 Jan; 21(1):22-34. PubMed ID: 25344374
[TBL] [Abstract][Full Text] [Related]
9. Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis.
Perumal JS; Foo F; Cook P; Khan O
Mult Scler; 2012 Aug; 18(8):1197-9. PubMed ID: 22252465
[TBL] [Abstract][Full Text] [Related]
10. Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis.
Daniels GH; Vladic A; Brinar V; Zavalishin I; Valente W; Oyuela P; Palmer J; Margolin DH; Hollenstein J
J Clin Endocrinol Metab; 2014 Jan; 99(1):80-9. PubMed ID: 24170099
[TBL] [Abstract][Full Text] [Related]
11. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
Coles AJ; Twyman CL; Arnold DL; Cohen JA; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Miller T; Fisher E; Sandbrink R; Lake SL; Margolin DH; Oyuela P; Panzara MA; Compston DA;
Lancet; 2012 Nov; 380(9856):1829-39. PubMed ID: 23122650
[TBL] [Abstract][Full Text] [Related]
12. Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab.
Meunier B; Rico A; Seguier J; Boutiere C; Ebbo M; Harle JR; Schleinitz N; Pelletier J
Mult Scler; 2018 May; 24(6):811-813. PubMed ID: 29359614
[TBL] [Abstract][Full Text] [Related]
13. Acute myocardial infarction associated with initial alemtuzumab infusion cycle in relapsing-remitting multiple sclerosis.
Romba MC; Newsome SD; McArthur JC
Mult Scler Relat Disord; 2019 Sep; 34():100-102. PubMed ID: 31252364
[TBL] [Abstract][Full Text] [Related]
14. A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.
Cuker A; Coles AJ; Sullivan H; Fox E; Goldberg M; Oyuela P; Purvis A; Beardsley DS; Margolin DH
Blood; 2011 Dec; 118(24):6299-305. PubMed ID: 21960587
[TBL] [Abstract][Full Text] [Related]
15. Early neutropenia with thrombocytopenia following alemtuzumab treatment for multiple sclerosis: case report and review of literature.
Maniscalco GT; Cerillo I; Servillo G; Napolitano M; Guarcello G; Abate V; Improta G; Florio C
Clin Neurol Neurosurg; 2018 Dec; 175():134-136. PubMed ID: 30419425
[TBL] [Abstract][Full Text] [Related]
16. The outlook for alemtuzumab in multiple sclerosis.
Williams T; Coles A; Azzopardi L
BioDrugs; 2013 Jun; 27(3):181-9. PubMed ID: 23558379
[TBL] [Abstract][Full Text] [Related]
17. Ocrelizumab for Post-Alemtuzumab Paradoxical Disease Activity in Highly Active Multiple Sclerosis.
Adamec I; Habek M
Clin Neuropharmacol; 2022 Sep-Oct 01; 45(5):139-141. PubMed ID: 36093911
[TBL] [Abstract][Full Text] [Related]
18. Thyroid disorders in alemtuzumab-treated multiple sclerosis patients: a Belgian consensus on diagnosis and management.
Decallonne B; Bartholomé E; Delvaux V; D'haeseleer M; El Sankari S; Seeldrayers P; Van Wijmeersch B; Daumerie C
Acta Neurol Belg; 2018 Jun; 118(2):153-159. PubMed ID: 29372482
[TBL] [Abstract][Full Text] [Related]
19. Alemtuzumab: a review of its use in patients with relapsing multiple sclerosis.
Garnock-Jones KP
Drugs; 2014 Mar; 74(4):489-504. PubMed ID: 24604792
[TBL] [Abstract][Full Text] [Related]
20. Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.
Hersh CM; Cohen JA
Immunotherapy; 2014; 6(3):249-59. PubMed ID: 24762071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]